Please ensure Javascript is enabled for purposes of website accessibility

Why Dynavax Stock Crushed It Today

By Keith Speights – Jun 1, 2020 at 3:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Last week's momentum continued for the high-flying biotech stock.

What happened

Shares of Dynavax (DVAX 0.00%) were skyrocketing 30.2% higher as of 3:47 p.m. EDT on Monday. The biotech didn't report any new developments today. However, the huge gain likely stemmed from last week's momentum, which was the result of positive comments from Dynavax's partner, Sinovac, as well as insider buying by Dynavax's interim chairman of the board, Andrew Hack.  

So what

Investors need to be cautious about putting too much focus on the comments last week made by Sinovac researcher Luo Baishan. When asked about the prospects for the COVID-19 vaccine being developed by Sinovac using Dynavax's CpG 1018 adjuvant, Baishan replied that he was 99% sure that the vaccine would be successful. However, Helen Yang, senior director of investor relations at Sinovac, was more measured in her reply to a similar question, stating: "It's very hard to say, very difficult to say at the moment. There are uncertainties, but the data: so far, so good."

$1 bill folded into an arrow pointing up

Image source: Getty Images.

It's definitely encouraging, though, that a key insider at Dynavax made a big bet on the company's future. Andrew Hack bought $5 million worth of shares last week. This brings Hack's total ownership to more than 8.5 million shares -- around 7.8% of Dynavax's total outstanding shares. 

Now what

The main thing to watch with Dynavax right now is the progress of the experimental COVID-19 vaccines being developed by various drugmakers using its CpG 1018 adjuvant. In addition, the company expects to report final immunogenicity data from its study of Heplisav-B in patients on hemodialysis in the second half of this year.

Meanwhile, don't be surprised if the biotech stock remains highly volatile. That's to be expected when there's a high short percentage of float, as is the case with Dynavax.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Dynavax Technologies Corporation Stock Quote
Dynavax Technologies Corporation
DVAX
$10.24 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.